PerkinElmer, Inc. (PKI) |
| 115.24 -1.06 (-0.91%) 05-15 16:03 |
| Open: | 115.98 |
| High: | 117.21 |
| Low: | 114.67 |
| Volume: | 1,633,024 |
| Market Cap: | 14,456(M) |
| PE Ratio: | 41.45 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 17.80 |
| Resistance 1: | 15.24 |
| Pivot price: | 14.67 |
| Support 1: | 13.87 |
| Support 2: | 13.03 |
| 52w High: | 170 |
| 52w Low: | 113.17 |
PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment offers a suite of solutions, including reagents, informatics, and detection and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for the environmental, food, and industrial markets that enable its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
| EPS | 0.420 |
| Book Value | 4.160 |
| PEG Ratio | 0.00 |
| Gross Profit | 1.192 |
| Profit Margin (%) | 14.06 |
| Operating Margin (%) | 16.71 |
| Return on Assets (ttm) | 7.2 |
| Return on Equity (ttm) | 10.6 |
Fri, 19 May 2023
PerkinElmer Completes Transformation to Become Revvity - Yahoo Finance
Mon, 13 Mar 2023
PerkinElmer Completes Divestiture of its Applied, Food and Enterprise Services Businesses - Business Wire
Fri, 24 Feb 2023
PerkinElmer Launches EnVison Nexus Multimode Plate Reader to Drive Improved Research and Discovery Workflows - Business Wire
Tue, 02 Aug 2022
PerkinElmer Accelerates Transformation Into High Growth, High Margin Life Sciences and Diagnostics Company - Technology Networks
Mon, 01 Aug 2022
PerkinElmer divests three business units in $2.45 bln deal - Reuters
Thu, 20 Jan 2022
PerkinElmer Inc. stock underperforms Thursday when compared to competitors - MarketWatch
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |